Related Experiment Video
Updated: Aug 10, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
The genetic determinants of the CYP3A5 polymorphism
Pharmacogenetics
|December 12, 2001
Summary
A genetic variant (g.6986G>A) in intron 3 is the main cause of CYP3A5 protein variation. This finding helps understand drug metabolism differences across ethnic groups.
Area of Science:
- Pharmacogenomics
- Drug Metabolism
- Cytochrome P450 Research
Background:
- Cytochrome P450 (CYP) 3A proteins are crucial for metabolizing approximately 50% of drugs.
- Functional similarities among the four human CYP3A genes complicate the study of individual gene contributions to hepatic CYP3A activity.
Purpose of the Study:
- To investigate the expression of CYP3A5 and its genetic determinants in Caucasian liver samples.
- To identify genetic markers associated with increased CYP3A5 expression.
Main Methods:
- Analysis of CYP3A5 expression in 183 Caucasian liver samples.
- High-density mapping of CYP3A5 variants to identify genetic markers.
- Genotyping for the g.6986G>A single nucleotide polymorphism (SNP) and other variants.
Main Results:
- CYP3A5 expression is elevated in 10% of Caucasian livers studied.
- The SNP g.6986G>A in intron 3 is identified as the primary cause of CYP3A5 protein polymorphism.
- Allele frequencies of the functional g.6986A variant vary significantly across ethnic groups (5% Caucasian to 73% African-American).
- A frame-shift mutation (CYP3A5*7) further impacts CYP3A5 expression in African-Americans carrying the g.6986A variant.
Conclusions:
- The g.6986G>A SNP is a key determinant of CYP3A5 expression and drug metabolism variability.
- Understanding CYP3A5 genetic variations is essential for predicting drug response and efficacy.
- These findings contribute to elucidating the genetic basis of CYP3A family expression variability.
Related Concept Videos
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...